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Abstract 
A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in 
the oxidosqualene cyclase1 (OSC)-mediated cyclization of to lanosterol were prepared from 
Grundmann's ketone. Screening on OSCs from five different organisms revealed interesting 
activities and selectivities of some of the compounds. A N,N-dimethylaminopropyl derivative 
showed promising inhibition of T. cruzi OSC in combination with low cytotoxicity, and showed 
significant reduction of cholesterol biosynthesis in a human cell line. 
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Introduction 
Sterol biosynthesis is a complex metabolic pathway in which two sharply different sections 
are well recognizable: an “assembly section” which is devoted to build the open triterpene 
2,3-oxidosqualene starting from the common lipid precursor acetyl-CoA, and a “tailoring 
section” which remodels the sterol intermediates to generate the end-product (cholesterol, 
                                                 
1 OSC = oxidosqualene cyclase 
ergosterol or phytosterols, in animal, fungal or plant cells, respectively). The two sections are 
connected by the cyclization of 2,3-oxidosqualene, one of the most outstanding mono-
enzymatic reactions (if not the most one), that confers the steroid shape to the open triterpene 
oxidosqualene. This reaction is catalyzed by enzymes belonging to the family of 
oxidosqualene cyclases (OSC), which form lanosterol in non-photosynthetic organisms and, 
mostly, cycloartenol in photosynthetic organisms [1,2].  
Cyclization of 2,3-oxidosqualene is triggered by the stereospecific protonation of the epoxide 
ring of the substrate and proceeds through the generation of several carbocationic high energy 
intermediates (HEIs) both during the formation of the new carbon-carbon bonds for the 
closure of the four rings-steroid scaffold (in the sequence pro-C4, C10, C8, C13 and  C20) 
and during the rearrangement of the protosteryl carbocation pro- C20 (in the sequence pro-
C17, C13, C14, and C8 or C9 depending on the product) till the removal of a proton and 
formation of lanosterol or cycloartenol. Studies for unravelling the above complex cyclization 
reaction had involved a number of laboratories for over fifty years, covering a complete list of 
expertises and methodologies, from chemical mimicking to protein purification, from 
inhibitory assays to site-directed mutagenesis [3], till the crystallization of squalene and 
oxidosqualene cyclizing enzymes [4,5,6]. 
Oxidosqualene cyclases have been considered attractive targets for designing cholesterol 
lowering [7], antifungal [8,9], and antiparasitic agents [10,11,12]. Recently, inhibitors of 
oxidosqualene cyclase proved to be effective as anticancer agents against human cancer cells 
from various tissue origins [13].  
A common concept in the development of inhibitors of sterol (and other) biosynthesis is 
mimicking of the extremely short-lived carbocationic HEIs, most commonly accomplished by 
compounds having (a) a protonable aliphatic amino group, or (b) an aliphatic amine-N-oxide, 
or (c) a quaternary ammonium or pyridinium group at the pertinent position. The above 
molecule-designing strategy proved to be particularly prolific in designing inhibitors of OSC, 
being its reaction mechanism characterized by the consecutive formation of a number of 
carbocationic HEIs. Dozens of inhibitors have been synthesized during the last thirty years: (i) 
azadecalin and azasqualene derivatives [14], (ii) Ro 48-8071 and related benzophenone 
derivatives designed by Roche [7,15] and AstraZeneca groups [16], (iii) pyridinium ion based 
inhibitors [9,10,17], (iv) umbelliferone derivatives [18,19], (v) sulfur-containing analogues 
[20], and others like BIBX 79 [21] (Fig. 1). 
 
 Figure 1. Representative inhibitors of oxidosqualene cyclases (OSC).  
 
In continuation of our previous work on the development of inhibitors of oxidosqualene 
cyclases from various organisms [12,18,19] and other enzymes in ergosterol [22] and 
cholesterol biosynthesis [23,24,25] we describe here a new chemotype of oxidosqualene 
cyclase inhibitors that was designed with the following rationale: in order to achieve high 
affinity to the enzymes, we introduced a homochiral equivalent of the rings C and D of sterols 
and the sterol side chain by using Grundmann's ketone (1) [26] as a building block. To this 
bicyclic scaffold we attached an aminopropyl chain, ending up with secosteroid-like 
molecules, in which the protonable nitrogen might mimic two of the early cationic HEIs of 
the cyclization cascade. Through free rotation of the aminopropyl chain the protonated amino 
group is able to occupy the position of the first occurring HEI at C-2 of the squalene chain (A; 
representing pro-C4 of the emerging sterol) as well as that of the pro-C10 HEI (B) (Figure 2). 
 
  
Figure 2. Two rotamers of the target compounds (top row), the pro-C4 HEI (A) and the pro-
C10 HEI (B) of lanosterol biosynthesis (bottom row). 
 
The newly designed molecules were assayed on five different OSCs, with the aim of identifying 
lead molecules for the development of new drugs. All the enzymes, namely lanosterol synthases 
from Saccharomyces cerevisiae, Pneumocystis carinii, Trypanosoma cruzi, and Homo sapiens, 
as well as the cycloartenol synthase from Arabidopsis thaliana, were expressed in an ERG7-
deficient yeast (Saccharomyces cerevisiae) strain [27]. Cycloartenol synthase has been included 
in the present study in order to ascertain if the critical amino acid differences between lanosterol 
and cycloartenol synthases would influence their sensitivity to our inhibitors [28]. 
In order to confirm activities of the inhibitors in a cellular system, selected compounds were 
assayed for their inhibition of total cholesterol biosynthesis in a human cell line [24].  
Some of our new molecules proved to be highly effective and specific, and offer interesting 
clues to the development of new OSC inhibitors, especially as antiparasitic drugs.  
 
2. Results and Discussion 
 
2.1. Chemistry 
 
Grundmann's ketone (also named Windaus ketone; 1) [26] was obtained in high yield by 
ozonolysis of cholecalciferol (vitamin D3), but by using a novel workup procedure (treatment 
of the ozonolysis mixture with water, followed by extraction with pentane). In this manner the 
well-documented epimerization of 1 at C-3a [29] could be avoided. The ketone was reacted 
with cyclopropylmagnesium bromide to give the tertiary alcohol 2. NMR and GC analysis of 
the crude product revealed that a mixture of epimers (putatively at C-3a and/or C-4) was 
formed. Since the stereocenters at both C-3a and C-4 were to be destroyed in the subsequent 
step, intermediate 2 was purified only superficially over a short silica column. Crude 2 was 
treated with hydrogen bromide in glacial acetic acid [30] to give the bromopropyl derivative 3 
in high yield. The underlying homoallylic rearrangement led to a product with an endocyclic 
tetrasubstituted olefin, namely a product with only three, moreover configurationally stable 
asymmetric centers. Finally, reaction of 3 with primary and cyclic as well as acyclic 
secondary amines gave the desired aminopropylindene derivatives 4 - 7. The piperidine 
substituent was selected since it might additionally mimic the ring A of the sterol, the N-allyl-
N-methyl motif was selected, since it can be found in the benzophenone-type OSC inhibitor 
Ro-48-8071 (Fig. 1), which had recently been co-crystallized with human OSC and shown to 
bind to the enzyme in a manner like the pro-C-4 HEI A (Figure 2) does [5]. Since 
carbocationic HEIs can also be mimicked by tertiary amine N-oxides [31] and N-
alkylpyridinium salts [9], N-oxide 9 was prepared by oxidation of tertiary amine 6 with meta-
chloroperbenzoic acid (MCPBA), and pyridinium salt 8 by reaction of the intermediate 3 with 
pyridine. 
 
 
 
Scheme 1. Reagents and conditions: (a) cyclopropylmagnesium bromide, THF, reflux, 3.5 h, 
(69%); (b) HBr in acetic acid, 10 °C, 30 min (82%); (c) aliphatic amine, acetonitrile, 20 or 40 
°C, 72 h (56 - 98%); (d) pyridine, reflux, 1 h (82%); (e) MCPBA, chloroform, 0 °C, 30 min 
(82%). 
2.2. Effect of inhibitors on OSCs from different organisms  
 
Activity of the compounds as inhibitors of OSC was tested by incubating homogenates 
prepared from cell cultures of different recombinant yeast strains with radiolabelled 2,3-
oxidosqualene in the presence of increasing inhibitor concentrations. A comparative 
determination of OSC inhibitory activity of the compounds on the recombinant enzymes 
revealed that compound 5, exclusively bearing a secondary amino group in the side-chain, 
was inactive on any OSC under investigation, while the remaining compounds showed both a 
strong structure-linked dependence and, other than the reference inhibitor Ro 48-8071, 
considerable differences in susceptibility among the enzymes from different organisms (Table 
1). 
OSC from P. carinii revealed to be significantly inhibited only by 4, a molecule which on the 
other hand displayed comparably high activity on all assayed enzymes (IC50 range: 0.6-1.5 
µM). 
Among the target enzymes, cycloartenol synthase from the plant A. thaliana appeared to be 
the most sensitive to the inhibitors, with IC50 values ≤1 µM for five of the six compounds 
assayed (Table 1). Inhibitors, which bear bulky piperidine and pyridinium rings show the 
most distinct selectivity for the cycloartenol synthase of A. thaliana. The oxidosqualene 
cyclases of the other species tested are more sensitive to inhibitors with small substituents at 
the nitrogen, and show no or only week inhibitory effects if bulky residues were chosen. 
Interestingly, similar organism-dependent differences were observed in a previous study of 
ours [19], in which a series of aminoalkyl umbelliferone derivatives were assayed on the same 
set of OSCs as in the present study. In that study, the most dramatic difference between plant 
and other OSCs was observed with a compound bearing a morpholine ring, which proved to 
be highly effective on the cyclase from A. thaliana, while resulted almost ineffective against 
the other OSCs. Pyridinium salt 8 showed negligible inhibition of T. cruzi OSC, what is in 
contrast to previous reports claiming that the significant antitrypanosomal activities of simple 
N-terpenyl pyridinium salts can be attributed to an inhibition of T. cruzi OSC [10].  
Comparison of the inhibitory effects of the N,N-dimethylamino compound 6 and the 
corresponding N-oxide 9 revealed that the tertiary amine showed higher activities on all 
OSCs, but parallels in species selectivity are evident. This suggests that steric parameters 
might be crucial for species selectivity in this new chemotype of OSC inhibitors. Most 
interestingly, both the N,N-dimethylamino compound 6 and the N-oxide 9 show strong 
inhibition of T. cruzi OSC. In contrast to the reference inhibitor Ro 48-8071, however, these 
two compounds show considerable selectivity with respect to human OSC (factors ≥7), a 
property that is worth deeply exploring in designing new anti-trypanosomal agents.  
 
 
Table 1. Effect of inhibitors on oxidosqualene cyclase activity of homogenates prepared from 
yeast recombinant strains SMY8 expressing S. cerevisiae, P. carinii, T. cruzi, A. thaliana and 
H. sapiens OSCs.  
  
 
Compound 
IC50 (μM)a 
OSCb  
S. cerevisiae 
OSCb 
P. carinii 
 OSCb  
T. cruzi 
OSCc  
A. thaliana 
OSCb  
H. sapiens 
4 1.5 0.9 0.8 0.6 1.0 
5 >20 >20 >20 >20 >20 
6  1.3 13 0.6 0.3 4.5 
7  2.1 17 >20 0.5 11.9 
8 4.2 11 >20 0.2 12.5 
9 2.5 15 3 1.3 >20 
Ro 48-
8071d 
 
0.21 0.34 0.90 1.75 0.17 
 
a Values are the means of two separate experiments, each one carried out in duplicate. The 
maximum deviations from the mean were less than 10%.  
b Lanosterol synthase 
c Cycloartenol synthase 
d From ref. [12] 
 
 
2.2.1. Cytotoxic activity 
A first screening for cytotoxic activities of the compounds was performed in a MTT assay 
according to the method of Mosmann [32] on human leukaemia HL-60 cells. Cisplatin was 
used as reference. The results are shown in Table 2. Significant cytotoxicity (IC50 <10 M) 
was recorded only for the pyridinium compound 8. Probably, this can be attributed to the 
detergent-like properties of this compound. N-Oxide 9 showed moderate cytotoxicity (IC50 = 
20 M), what makes it less attractive for further drug development compared to its tertiary 
amino analogue 6, which is, like all other primary and secondary amines investigated here, 
devoid of cytotoxicity. In contrast, reference OSC inhibitor Ro 48-8071 showed noteworthy 
cytotoxicity (IC50 = 8 M). BIBX 79 (Fig. 1), another prominent OSC inhibitor, showed no 
significant cytotoxicity. This shows, that the inhibition of cholesterol biosynthesis is not 
necessarily correlating with the cytotoxicity of the inhibitors.  
 
Table 2. Cytotoxic activities of investigated compounds against HL-60 cells determined by 
MTT assay. 
_________________________________________________________________ 
Compound   IC50 [M] 
_________________________________________________________________ 
Cisplatin    5 
Ro 48-8071   8  
BIBX 79   > 50 
4    >100 
5    >100 
6    >100 
7    >100 
8    3.5 
9    20 
________________________________________________________________ 
 
2.2.2 Assay for inhibition of cholesterol biosynthesis in cells 
Compounds 4 and 6, which showed significant inhibition of human OSC in the in vitro 
screenings (Table 1), were subjected to a whole cell assay on human HL-60 cells in order to 
investigate their activity at the cellular level. This assay is based on a method described by us 
previously [24]. The inhibitors were tested in triplicates at a concentration of 1 µM. 
Incubation in the presence of 2-13C-acetate leads to the incorporation of 13C atoms into the 
cholesterol molecules biosynthesized during the incubation period, and allows us to 
distinguish newly synthesised cholesterol from unlabelled matrix cholesterol that was present 
in the cells before incubation, by GC-MS. At a fixed concentration of 1 µM 4 and 6 led to a 
decrease of overall cholesterol biosynthesis of >90% compared to untreated control samples. 
At the same concentration Ro 48-8071 led to a decrease of >90%, for BIBX 79 a reduction of 
60% was recorded.  
 3. Conclusion 
 
This paper describes the design, synthesis, and biological evaluation of a series of 
aminopropylindenes as a new chemotype of oxidosqualene cyclase (OSC) inhibitors. Our 
concept included the design of inhibitors which contain typical structural elements of sterols 
(rings C+D and the lipophilic side chain), introduced by utilizing Grundmann's ketone as a 
building block, as well as a protonable or cationic functional group at a position where high 
energy intermediates of the OSC-catalyzed cyclization reaction occur. The compounds were 
tested in vitro for inhibition of five different oxidosqualene cyclases, among which four 
lanosterol synthases (from Saccharomyces cerevisiae, Trypanosoma cruzi, Pneumocystis 
carinii and Homo sapiens), and one cycloartenol synthase (from Arabidopsis thaliana). The 
screening results of this first, relatively small collection of inhibitors gave first insights into 
structure-activity-relationships, showing that the size and charge of the side chain have 
significant impact on activity, selectivity, and cytotoxicity of the compounds. The lack of 
cytotoxicity of the tertiary amines 4-7 is remarkable. 
In a whole cell assay on a human cell line compounds 4 and 6 showed strong inhibition of 
total cholesterol biosynthesis, indicating that this class of inhibitors has proper physico-
chemical properties for being active in living cells.  
The concept of combining a significant partial structure of the steroid backbone with 
functional groups which are able to mimic cationic high energy intermediates, is promising 
for further evaluation.  
 
4. Experimental 
 
4.1. Chemistry 
 
Ozonolyses were performed on a Fisher Scientific 502 Ozon Generator (Fisher Scientific, 
Schwerte, Germany). Melting points were determined by open tube capillary method on a 
Büchi melting point B-450 apparatus and are uncorrected. IR spectra were obtained on a 
Perkin Elmer FT-IR: Paragon 1000 spectrometer. NMR spectra were recorded on Jeol JNMR-
GX 400 (400 MHz) and Jeol JNMR-GX 500 (500 MHz) spectrometers with tetramethylsilane 
as an internal standard. J values are given in Hz. Mass spectra (MS) were run by chemical 
impact (CI; reactant gas: methane) on a Hewlett Packard 5989 A mass spectrometer with 
59980 B particle beam LC/MS interface, and by electron impact (EI) at 70 eV on a Jeol JMS 
GCmate II. Solvents were of HPLC grade or p.a. grade, if not they were distilled before use. 
All chemicals were purchased from Sigma Aldrich (Schnelldorf, Germany) and Acros 
Organics (Geel, Belgium). Reactions were monitored by thin-layer chromatography (TLC) 
using pre-coated plastic sheets POLYGRAM SIL G/UV254 from Macherey-Nagel (Düren, 
Germany). Merck silica gel 60 was used as stationary phase for flash column chromatography 
(FCC). 
The OSC substrate, 2,3-oxidosqualene (OS), was prepared as previously described [33]. 
Labelled [14C]-(3S)2,3-oxidosqualene was obtained through biological synthesis by 
incubating pig liver S10 supernatant with R,S[2-
14C]mevalonic acid (1 µCi, 55 mCi/mmol, 
2.04 GBq/mmol) (Amersham Pharmacia Biotech, U.K), in the presence of OSC inhibitor 
U14266A [34].  
 
 
(1R,3aR,7aR)-1-[(R)-1,5-Dimethylhexyl]-7a-methyloctahydroinden-4-one (Grundmann’s 
ketone; 1) 
A solution of cholecalciferol (5.00 g, 13.0 mmol) in methanol (100 mL) was cooled to -30 to -
40 °C and ozone was bubbled through the solution (60 L/h) for 30 minutes. The solution was 
treated with 50 mL water, concentrated under reduced pressure to 80 mL volume, and 
extracted with pentane (3 x 100 mL). The combined organic layers were dried over 
magnesium sulphate and concentrated under reduced pressure. The crude product was 
purified by FCC (hexane:ethyl acetate 10:1) to yield 3.35 g (97%) of Grundmann's ketone as a 
colourless oil. 20][ D  = + 42.1; IR (NaCl): ν̃ = 2958 cm
-1, 1677, 1418, 1245, 1209, 1144, 961; 
1H NMR (CDCl3): δ = 2.42 ppm (dd, J1 = 11.8, J2 = 7.5 Hz, 1 H, 3a-H), 2.29-2.18 (m, 2 H, 5-
H), 2.12 (m, 1 H, 7-H), 2.00 (m, 1 H, 6-H), 1.95-1.85 (m, 2 H, 3-H, 6-H), 1.73 (m, 1 H, 2-H), 
1.61-1.28 (m, 8 H, 1-H, 2-H, 3-H, 7-H, 1’-H, 2’-H, 3’-H, 5’-H), 1.18-1.00 (m, 4 H, 2’-H, 3’-
H, 4’-H), 0.95 (d, J = 6.6 Hz, 3 H, 1’-CH3), 0.86 (d, J = 6.7 Hz, 3 H, 6’-H), 0.85 (d, J = 6.6 
Hz, 3 H, 5’-CH3), 0.65 (s, 3 H, 7a-CH3); 13C NMR (CDCl3): δ = 212.3 ppm, 62.0, 56.8, 49.9, 
41.0, 39.4, 39.0, 35.9, 35.5, 28.0, 27.5, 24.1, 23.7, 22.8, 22.5, 19.0, 18.7, 12.5; MS (CI): m/z 
(%) = 265 (64) [M+H]+, 247 (100); MS (EI, 70 eV): m/z (%) = 264 (19) [M]+; 125 (100), 111 
(61); HRMS (EI, 70 eV): m/z = 264.2495 [M]+, calcd for C22H41N: 264.2453. 
 
(1R,7aR)-4-(3-Bromopropyl)-2,3,5,6,7,7a-hexahydro-7a-methyl-1-[(R)-1,5-dimethyl-
hexyl]-1H-indene (3) 
Under nitrogen, a solution of 800 mg (3.03 mmol) Grundmann's  ketone (1) in 20 mL 
anhydrous THF was added dropwise to 9.0 mL of solution of cyclopropylmagnesium bromide 
(0.5 M in THF; 4.5 mmol) with stirring, and the mixture was refluxed for 3.5 h. After cooling 
to ambient temperature, the mixture was poured into ice-water (20 mL), and solid ammonium 
chloride is added with stirring until the precipitate dissolved. The mixture was extracted with 
diethyl ether (3 x 20 mL), and the combined organic layers were dried over magnesium 
sulphate. The oily residue was purified by FSC (cyclohexane:ethyl acetate 20:1) to give crude 
tertiary alcohol 2. (640 mg; about 69%; mixture of isomers). This product was dissolved in 
glacial acetic acid (2 mL) and 0.30 mL of a solution of HBr in glacial acetic acid (40%) was 
added. The reaction mixture was stirred under a nitrogen atmosphere for 30 min and then 
extracted with diethyl ether (3 x 20 mL). The combined organic layers were dried over 
magnesium sulphate and concentrated under reduced pressure. The crude product was 
purified by FCC (heptane) to yield 632 mg (82% calculated on crude 2; 56% over both steps ) 
of 3 as colourless oil. 20][ D  = +48.2.  IR (NaCl): ν̃ = 2953 cm
-1, 2858, 1465, 1368, 1247; 1H 
NMR (CDCl3): δ = 3.36 ppm (m, 2 H, 3’-H), 2.33-2.18 (m, 2 H, 3-H), 2.14-2.07 (m, 1 H, 2-
H), 2.00-1.74 (m, 7 H, 1’-H, 2-H, 2’-H, 5’-H, 7-H), 1.73-1.61 (m, 2 H, 6-H), 1.55-1.48 (m, 2 
H, 1’’-H, 5’’-H), 1.40-1.02 (m, 9 H, 1-H, 2’’-H, 3’’-H, 4’’-H, 5-H, 7-H), 0.94 (d, J = 6.6 Hz, 
3 H, 1’’-CH3), 0.87 (d, J = 6.6 Hz, 3 H, 5’’-CH3), 0.86 (d, J = 6.6 Hz, 3 H, 6’’-H), 0.85 (s, 3 
H, 7a-CH3); 
13C NMR (CDCl3): δ = 144.1 ppm, 124.5, 56.4, 43.1, 39.6, 37.4, 36.0, 34.7, 33.8, 
32.1, 31.4, 28.0 (2 C), 27.1, 25.3, 23.8, 22.8, 22.6, 19.5, 19.0, 18.4; MS (CI): m/z (%) = 371 
(34) [M+H]+, 369 (40) [M+H]+, 355 (4), 353 (2), 257 (61), 255 (50), 127 (100); MS (EI, 70 
eV): m/z (%) = 370 (2) [M]+, 368 (4) [M]+, 355 (8), 353 (10), 257 (90), 255 (100); Anal. 
Calcd for C21H37Br (%): C 68.28, H 10.10. Found C 68.40, H 10.23. 
 
N-Allyl-N-methyl-{3-[(1R,7aR)-1-[(R)-1,5-dimethylhexyl]-7a-methyl-2,3,5,6,7,7a-
hexyhydro-1H-inden-4-yl]-propyl}amine (4) 
To a solution of bromo compound 3 (0.18 g, 0.49 mmol) in 5.0 mL acetonitrile and N-
allylmethylamine (3.0 mL, 1.8 mmol) was added, and the mixture was stirred at room 
temperature for 72 h under a nitrogen atmosphere. Then, a NaHCO3 solution (20 mL, 5 %) 
was added, and the mixture was extracted with methylene chloride (3 x 20 mL). The 
combined organic layers were dried over sodium sulphate and concentrated under reduced 
pressure. The crude product was purified by FCC (heptane:ethyl acetate:EDMA (N-ethyl-
N,N-dimethylamine) 8:2:0.1) to yield 98 mg (56%) of 4 as yellow oil. 20][ D  = +46.9.  IR 
(NaCl): ν̃ = 3075 cm-1, 2950, 2867, 2784, 1835, 1733, 1643, 1463, 1367, 995; 1H NMR 
(CDCl3): δ = 5.91-5.81 ppm (m, 1 H, 2’’’-H), 5.19-5.14 (m, 2 H, 3’’’-H), 3.00 (d, J = 6.6 Hz, 
2 H, 1’’’-H), 2.33-2.23 (m, 4 H, 1-H, 3’-H), 2.21 (s, 3 H, N-CH3), 1.98-1.80 (m, 6 H, 2’-H, 3-
H, 5’-H, 7’-H), 1.71-1.61 (m, 2 H, 6’-H), 1.57-1.49 (m, 3 H, 2-H, 5’’-H), 1.44-1.31 (m, 4 H, 
1’’-H, 2’-H, 2’’-H, 3’’-H), 1.19-1.05 (m, 6 H, 1’-H, 2’’-H, 3’’-H, 4’’-H, 7’-H), 0.94 (d, J = 
6.6 Hz, 3 H, 1’’-CH3), 0.87 (d, J = 6.6 Hz, 3 H, 5’’-CH3) 0.86 (d, J = 6.6 Hz, 3 H, 6’’-H),  
0.84 (s, 3 H, 7a’-CH3); 13C NMR (CDCl3): δ = 142.7 ppm, 135.8, 125.9, 117.5, 61.0, 57.1, 
56.4, 43.0, 42.0, 39.6, 37.5, 36.0, 34.8, 31.3, 28.0, 27.9, 27.1, 25.6, 25.2, 23.8, 22.8, 22.6, 
19.6, 19.0, 18.4; MS (CI): m/z (%) = 360 (100) [M+H]+, 358 (12), 344 (4), 175 (6), 110 (83); 
MS (EI, 70 eV): m/z (%) = 359 (6) [M]+, 344 (2), 330 (4), 246 (4), 175 (6), 147 (6), 133 (6), 
110 (100); Anal. Calcd for C25H45N (%): C 83.49, H 12.61, N, 3.89. Found C 83.35, H 12.70, 
N 3.89. 
 
N-Methyl-{3-[1R,7aR)-1-[(R)-1,5-dimethylhexyl]-7a-methyl-2,3,5,6,7,7a-hexahydro-1H-
inden-4-yl]-propyl}amine (5) 
Bomo compound 3 (0.20 g, 0.54 mmol) was dissolved in a 2 M solution of methylamine in 
THF (2.7 mL, 5.4 mmol), and the solution was stirred at 40 °C under a nitrogen atmosphere 
for 72 h. Then, a NaHCO3 solution (20 mL, 5 %) was added and the mixture was extracted 
with methylene chloride (3 x 20 mL). The combined organic layers were dried over sodium 
sulphate and concentrated under reduced pressure. The crude product was purified by FCC 
(heptane:ethyl acetate:EDMA 8:2:0.1) to yield 0.12 g (70%) of 5 as yellow oil. 20][ D  = +66.4. 
IR (NaCl): ν̃ = 3333 cm-1, 2952, 2869, 1465, 1367; 1H NMR (CDCl3): δ = 2.34-2.17 ppm (m, 
7 H, 1-H, 2-H, N-CH3, ), 1.96-1.78 (m, 6 H, 3-H, 3’-H, 5’-H, 7’-H), 1.71-1.61 (m, 2 H, 6’-H), 
1.60-1.31 (m, 7 H, 1’’-H, 2’-H, 2’’-H, 3’-H, 3’’-H, 5’’-H), 1.22-1.20 (m, 6 H, 1’-H, 2’’-H, 
3’’-H, 4’’-H, 7’-H), 0.93 (d, J = 6.6 Hz, 3 H, 1’’-CH3), 0.87 (d, J = 6.6 Hz, 3 H, 5’’-CH3), 
0.86 (d, J = 6.6 Hz, 3 H, 6’’-H), 0.84 (s, 3 H, 7a’- CH3); 13C NMR (CDCl3): δ = 142.7 ppm, 
126.4, 57.6, 56.5, 47.6, 43.0, 41.0, 37.6, 36.0, 34.9, 31.4, 28.1 (2x), 27.2, 25.6, 25.3, 23.9, 
22.9, 22.7, 19.6, 19.1, 18.5; MS (CI): m/z (%) = 320 (100) [M+H]+, 314 (14), 279 (19), 261 
(6), 187 (8), 167 (14), 149 (52), 113 (38); MS (EI, 70 eV): m/z (%) = 319 (1) [M]+; 317 (2), 
273 (2), 247 (2), 175 (6), 149 (19), 85 (41), 59 (100); HRMS (EI, 70 eV): m/z = 319.3259 
[M]+, calcd for C22H41N: 319.3239. 
 
N,N-Dimethyl-{3-[1R,7aR)-1-[(R)-1,5-dimethylhexyl]-7a-methyl-2,3,5,6,7,7a-hexahydro-
1H-inden-4-yl]-propyl}amine (6) 
Bromo compound 3 (0.15 g, 0.41 mmol) was dissolved in a 2 M solution of dimethylamine in 
THF (4.0 mL, 8.0 mmol), and the solution was stirred at room temperature under a nitrogen 
atmosphere for 24 h. Then, a NaHCO3 solution (20 mL, 5 %) was added, and the mixture was 
extracted with methylene chloride (3 x 20 mL). The combined organic layers were dried over 
sodium sulphate and concentrated under reduced pressure. The crude product was purified by 
FCC (heptane:ethyl acetate:EDMA 8:2:0.1) to yield 96 mg (70%) of 6 as yellow oil. 20][ D  = 
+25.6.  IR (NaCl): ν̃ = 2935 cm-1, 2812, 1464, 1368, 1265, 1042, 812; 1H NMR (CDCl3): δ = 
2.24-2.18 ppm (m, 10 H, 1-H, 2-H, N(CH3)2), 1.98-1.81 (m, 6 H, 3-H, 3’-H, 5’-H, 7’-H), 
1.71-1.62 (m, 2 H, 6’-H), 1.58-1.31 (m, 7 H, 1’’-H, 2’-H, 2’’-H, 3’-H, 3’’-H, 5’’-H), 1.24-
1.02 (m, 6 H, 1’-H, 2’’-H, 3’’-H, 4’’-H, 7’-H), 0.94 (d, J = 6.6 Hz, 3 H, 1’’-CH3), 0.87 (d, J = 
6.6 Hz, 3 H, 5’’-CH3), 0.86 (d, J = 6.6 Hz, 3 H, 6’’-H), 0.84 (s, 3 H, 7a’-CH3); 13C NMR 
(CDCl3): δ = 142.7 ppm, 126.0, 59.8, 56.5, 45.6, 43.0, 39.6, 37.5, 36.0, 34.8, 31.4, 28.0 (2x), 
27.2, 26.2, 25.2, 23.8, 22.8, 22.6 (2C), 19.6, 19.0, 18.4; MS (CI): m/z (%) = 334 (100) 
[M+H]+, 318 (4), 248 (4); MS (EI, 70 eV): m/z (%) = 333 (5) [M]+; 84 (51), 58 (100); HRMS 
(EI, 70 eV): m/z =  333.3378 [M]+, calcd for C23H43N: 333.3395; Anal. Calcd for C23H43N 
(%): C 82.81, H 12.99, N 4.20. Found C 82.63, H 13.27, N 4.17. 
 
N-{3-[1R,7aR)-1-[(R)-1,5-Dimethylhexyl]-7a-methyl-2,3,5,6,7,7a-hexahydro-1H-inden-4-
yl]-propyl}piperidine (7) 
A solution of bromo compound 3 (0.15 g, 0.41 mmol) in piperidine (0.70 g, 8.2 mmol) was 
stirred at room temperature under a nitrogen atmosphere for 3 d. Then, a NaHCO3 solution 
(20 mL, 5 %) was added, and the mixture was extracted with methylene chloride (3 x 20 mL). 
The combined organic layers were dried over sodium sulphate and concentrated under 
reduced pressure. The crude product was purified by FCC (heptane:EDMA 10:0.1) to yield 
0.15 g (98%) of 7 as yellow oil. 20][ D  = +41.6. IR (NaCl): ν̃ = 2935 cm
-1, 2812, 1464, 1368, 
1265, 1042, 812;  1H NMR (CDCl3): δ = 2.41-2.32 ppm (m, 4 H, 2-H, 6-H), 2.30-2.18 (m, 2 
H, 1’-H), 1.98-1.90 (m, 4 H, 3’-H, 5’’-H, 7’’-H), 1.89-1.80 (m, 2 H, 3’’-H), 1.76-1.66 (m, 2 
H, 6’’-H), 1.65-1.50 (m, 12 H, 2’-H, 2’’-H, 3-H, 4-H, 5-H, 5’’-H, 5’’’-H), 1.48-1.34 (m, 3 H, 
1’’’-H, 3’’-H, 3’’’-H), 1.23-1.06 (m, 6 H, 2’’’-H, 3’’’-H, 4’’’-H, 7’’-H), 0.95 (d, J = 6.6 Hz, 3 
H, 1’’’-CH3), 0.89 (d, J = 6.6 Hz, 3 H, 5’’’-CH3), 0.87 (d, J = 6.6 Hz, 3 H, 6’’’-H), 0.84 (s, 3 
H, 7a’’-CH3); 13C NMR (CDCl3): δ=142.7 ppm, 126.1, 59.3, 56.5, 54.7 (2x), 43.0, 39.6, 37.5, 
36.0, 34.8, 31.5, 28.0 (2x), 27.2, 26.2, 25.2, 24.6 (3C), 23.8, 22.8, 22.6, 19.6, 19.0, 18.4;  MS 
(CI): m/z (%) = 374 (100) [M+H]+, 266 (4), 124 (10); MS (EI, 70 eV): m/z (%) = 373 (12) 
[M]+; 124 (26), 111 (12), 98 (100); Anal. Calcd for C26H47N (%): C 83.57, H 12.68, N 3.75. 
Found C 83.19, H 12.66, N 3.54. 
 
N-{3-[1R,7aR)-1-[(R)-1,5-Dimethylhexyl]-7a-methyl-2,3,5,6,7,7a-hexahydro-1H-inden-4-
yl]-propyl}pyridinium bromide (8) 
A solution of bromo compound 3 (0.18 g, 0.49 mmol) in pyridine (0.40 g, 5.0 mmol) was 
stirred at reflux for 1 h. Then, the excess of pyridine was distilled off under reduced pressure,  
and the rsidue was crystallized from heptane to yield 0.18 g (82%) of 8 as yellowish solid, 
Mp. 63 °C. 20][ D  = +60.2. IR (KBr): ν̃ = 3416 cm
-1, 3126, 2953, 2868, 2190, 1486, 1465, 
1367; 1H NMR (CDCl3): δ = 9.48 ppm (d, J = 6.7 Hz, 2 H, 2-H, 6-H), 8.55 (dd, J1 = 7.9 Hz, J2 
= 1.2 Hz, 1 H, 4-H), 8.17 (dd, J1 = 7.9 Hz, J2 = 6.7 Hz, 2 H, 3-H, 5-H), 4.93 (t, J = 7.1 Hz, 2 
H, 1’-H), 2.15-2.04 (m, 6 H, 2’-H, 3’-H, 5’’-H), 1.97-1.91 (m, 2 H, 7’’-H), 1.90-1.78 (m, 3 H, 
2’’-H, 3’’-H), 1.69-1.63 (m, 2 H, 6’’-H), 1.52 (tq, J1 = J2 = 6.6 Hz, 1 H, 5’’’-H), 1.45-1.25 (m, 
4 H, 1’’’-H, 2’’-H, 2’’’-H, 3’’’-H), 1.17-1.03 (m, 5 H, 1’’-H, 2’’’-H, 3’’’-H, 4’’’-H), 0.92 (d, 
J = 6.6 Hz, 3 H, 1’’’-CH3), 0.87 (d, J = 6.6 Hz, 3 H, 5’’’-CH3), 0.85 (d, J = 6.6 Hz, 3 H, 6’’’-
H), 0.82 (s, 3 H, 7a’’-CH3); 13C NMR (CDCl3): δ = 145.2 ppm (2C), 145.1, 144.8, 128.5 (2C), 
123.6, 62.1, 56.3, 43.5, 39.5, 37.2, 35.9, 34.6, 30.3, 29.9, 28.0, 27.8, 27.0, 25.4, 23.8, 22.8, 
22.6, 19.4, 18.9, 18.5; MS (CI): m/z (%) = 369 (100) [M+H]+, 333 (12), 303 (14), 247 (14), 
220 (16), 179 (14), 159 (27), 127 (33), 107 (33); MS (EI, 70 eV): m/z (%) = 368 (20) [M]+, 
181 (40), 93 (100), 81 (16), 79 (22); Anal. Calcd for C26H42NBr x 2 H2O (%): C 64.45, H 
9.57, N 2.89. Found C 64.03, H 8.75, N 2.85. 
 
N,N-Dimethyl-{3-[1R,7aR)-1-[(R)-1,5-dimethylhexyl]-7a-methyl-2,3,5,6,7,7a-hexahydro-
1H-inden-4-yl]-propyl}amine-N-oxide (9) 
A solution of MCPBA (0.070 g, 0.40 mmol) in chloroform (5 mL) was added dropwise to a 
stirred solution of tertiary amine 6 (0.10 g, 0.33 mmol) in chloroform (5 mL). The mixture 
was stirred at 0 °C for 30 min, then washed with a saturated NaHCO3 solution (3 x 20 mL) 
and brine (2 x 20 mL). The organic layer was dried over sodium sulphate and evaporated 
under reduced pressure. The residue was purified by FCC (methanol) to yield 86 mg (82%) of 
9 as colourless viscous oil. 20][ D  = +22.4.  IR (NaCl): ν̃ = 2952 cm
-1, 1467, 1367, 957; 1H 
NMR (DMSO-d6): δ = 3.01 ppm (m, 2 H, 1-H), 2.96 (s, 6 H, N(CH3)2), 2.21-2.16 (m, 2 H, 2-
H), 1.93-1.80 (m, 8 H, 3-H, 3’-H, 5’-H, 7’-H), 1.68-1.60 (m, 2 H, 6’-H), 1.51 (tq, J1 = J2 = 6.6 
Hz, 1 H, 5’’-H), 1.44-1.23 (m, 4 H, 1’’-H, 2’-H, 2’’-H), 1.18-1.04 (m, 4 H, 1’-H, 2’’-H, 4’’-
H), 0.92 (d, J = 6.6 Hz, 3 H, 1’’-CH3), 0.89-0.83 (m, 11 H, 7a’-CH3, 3’’-H, 5’’-CH3, 6’’-H); 
13C NMR (DMSO-d6): δ = 142.4 ppm, 124.9, 69.9, 58.3, 55.9, 42.5, 38.9, 36.8, 35.3, 34.1, 
30.0, 27.3, 27.1, 26.6, 24.7, 23.1, 22.6, 22.3, 21.3, 18.9, 18.7, 18.2; MS (CI): m/z (%) = 350 
(5) [M+H]+, 334 (100), 320 (48); MS (EI, 70 eV): m/z (%) = 349 (8) [M]+; 333 (40), 320 (6), 
306 (8), 273 (16), 236 (33), 195 (52), 175 (60), 147 (52), 133 (72), 119 (60), 107 (100); 
HRMS (EI, 70 eV): m/z  = 349.3338 [M]+, calcd for C23H43NO: 349.3345. 
 
4.2 Strains of S. cerevisiae and cultural conditions 
The recombinant strains of S. cerevisiae, SMY8[pSM61.21] (MATa erg7::HIS3 hem1::TRP1 
ura3-52-trp1-63 LEU2::OSC S. cerevisiae his3-200 ade2 Gal+) expressing wild-type yeast 
OSC [36], SMY8[pBJ1.21] (MATa erg7::HIS3 hem1::TRP1 ura3-52 trp1-63 LEU2::OSC 
T. cruzi his3-200 ade2 Gal+) expressing T. cruzi OSC [27], SMY8[pBJ4.21] (MATa 
erg7::HIS3 hem1::TRP1 ura3-52 trp1-63 LEU2::OSC P. carinii his3-200 ade2 Gal+) 
expressing P. carinii OSC [27], SMY8[pSM60.21] (MATa erg7::HIS3 hem1::TRP1 ura3-52 
trp1-63 LEU2::OSC A. thaliana his3-200 ade2 Gal+) expressing A. thaliana OSC [37], 
and SMY8[pSOB1.1] (MATa erg7::HIS3 hem1::TRP1 URA3::OSC H. sapiens trp1-63 leu2-
3.112 his3-200 ade2 Gal+) expressing H. sapiens  OSC [38] were used. 
 
Cells of SMY8[pSM61.21], SMY8[pBJ1.21], SMY8[pBJ4.21] and SMY8[pSM60.21] were 
grown aerobically at 30 °C to early stationary phase in YPD medium (1% yeast extract, 2% 
peptone, 2% glucose) supplemented with hemin (0.013 mg/mL) and ergosterol (0.02 mg/mL). 
Hemin is needed in the medium as the SMY8 strains contain a mutation (hem1::TRP1) 
affecting the heme biosynthesis. The presence of a heme mutant background is necessary for 
the viability of lanosterol synthase mutants in aerobic conditions [36]. OSCs expression was 
induced in YPG medium (1% yeast extract, 2% peptone, 2% galactose) supplemented with 
hemin (0.013 mg/mL). A. thaliana OSC expression in SMY8[pSM60.21] was induced in 
YPG medium in presence of hemin (0.013 mg/mL) and ergosterol (0.02 mg/mL) 
Cells of SMY8[pSOB1.1] were grown aerobically at 30 °C to early stationary phase in 
synthetic complete medium without uracil SC-Ura (0.17% yeast nitrogen base, 0.2% amino 
acids, 0.5% ammonium sulphate), with glucose (2%) in presence of hemin (0.013 mg/mL) 
and ergosterol (0.02 mg/mL). Human OSC expression was induced in SC-Ura medium with 
galactose (2%) in presence of hemin (0.013 mg/mL).  
 
4.3 Enzyme assays 
Cell-free homogenates were obtained as described [38]. Briefly, after lysis of the cell wall 
with lyticase, the spheroplasts were homogenized with a Potter device. Proteins in the 
homogenate were quantified with a protein assay kit (Sigma), based on the method of Lowry 
modified by Peterson [39] using bovine serum albumin as a standard. 
OSC activity was assayed as described [38]. Briefly, the homogenates were incubated with 
labeled [14C]-(3S)-2,3-oxidosqualene (1000 cpm). The enzymatic reaction was terminated by 
the addition of KOH in methanol (10% w/v), the lipids were saponified at 80 °C for 30 min 
and nonsaponifiable lipids were extracted with petroleum ether. Extracts were spotted on TLC 
plates using n-hexane/ethyl acetate (85:15) as the developing solvent. The conversion of 
labelled substrate to labelled product was determined by using a System 200 Imaging Scanner 
(Hewlett-Packard, Palo Alto, CA, USA). 
OSC inhibition was carried out, as described above, by incubating the homogenates with 
labeled [14C]-(3S)-2,3-oxidosqualene (1000 cpm) in the presence of inhibitors. IC50 values 
(inhibitor concentrations that reduced the enzymatic conversion by 50%) were calculated by 
non-linear regression analysis of the residual activity versus the log of inhibitor concentration 
using statistical software from Genstat (NAG, Oxford, UK). 
 
4.4 MTT assay [32] 
HL 60 cells (German Collection of Microorganisms and Cell Cultures, DSMZ, Braunschweig, 
Germany) were maintained in RPMI 1640 medium (PAA Laboratories, Cölbe, Germany) 
containing 10 % fetal bovine serum (FBS, PAA Laboratories, Cölbe, Germany) without 
antibiotics at 37 °C in a humidified atmosphere containing 5 % CO2. Solutions of the 
compounds in DMSO (1 L, concentrations ranging from 10-9 to 10-4 mol/L) were incubated 
with 99 μL of a suspension of HL 60 cells (9 × 105 cells/mL) in RPMI 1640 medium with 10 
% FBS in 96 well plates for 24 h at 37 °C. Then, 10 μL of MTT solution in PBS (5 mg/mL) 
were added and the plate was incubated for another 2 h. The cells were quenched with 190 μL 
DMSO and after 1 h of continuously shaking of the plates a photometric evaluation on an 
ELISA plate reader MRX II (Dynex Technologies, Denkendorf, Germany; Software: 
Revelation 4.06) using the wavelength of 550 nm followed. The IC50-values were calculated 
by using Prism 4 (GraphPad Software, La Jolla, USA). 
 
4.5 Assay for cholesterol biosynthesis inhibition 
The whole cell assay for cholesterol biosynthesis inhibition was carried out on HL 60 cells as 
described by us previously [24]. 
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